Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2023
A prescription drug affordability board would lower prescription costs
1 February 2023 - Del. Rasoul is proposing Virginia create an independent panel of health care experts to review drug price ...
Posted by Michael Wonder on 02 Feb 2023
Drug prices increase 5.6% as Government ramps up pressure to lower costs
2 February 2023 - Restrained increases come as US implements the Inflation Reduction Act. ...
Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...
Posted by Michael Wonder on 02 Feb 2023
Medexus secures public reimbursement for Cuvposa in Quebec
1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...
Posted by Michael Wonder on 02 Feb 2023
Tezspire approved for self-administration in the US with a new pre-filled pen
2 February 2023 - First and only respiratory biologic without phenotype or biomarker limitations that offers the choice of administration ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 02 Feb 2023
Calliditas receives conditional marketing authorisation from UK MHRA for Kinpeygo in IgA nephropathy
2 February 2023 - Calliditas Therapeutics today announced that the MHRA of the United Kingdom has granted conditional marketing authorisation for ...
Posted by Michael Wonder on 02 Feb 2023
Professor John Skerritt retirement
2 February 2023 - Today, Professor John Skerritt has announced his decision to retire from his position of Deputy Secretary ...
Posted by Michael Wonder on 02 Feb 2023
FDA approves first oral treatment for anaemia caused by chronic kidney disease for adults on dialysis
1 February 2023 - Today, the US FDA approved Jesduvroq tablets (daprodustat) as the first oral treatment for anaemia caused by ...
Posted by Michael Wonder on 01 Feb 2023
FLAG Therapeutics receives rare paediatric disease designation for FLAG-003 for the treatment of children with diffuse intrinsic pontine glioma
31 January 2023 - FLAG Therapeutics announced today that FLAG-003, an investigational small molecule therapy for the treatment of diffuse intrinsic ...
Posted by Michael Wonder on 01 Feb 2023
Mark Cuban Cost Plus Drug Company and OncoPower team up to bring medication adherence and cost savings to cancer patients
30 January 2023 - Collaboration focuses on pricing transparency, affordable access, and engaging patients at home to ensure treatment adherence. ...
Posted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go ...
Posted by Michael Wonder on 01 Feb 2023
Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...
Posted by Michael Wonder on 01 Feb 2023
ABPI response to new MHRA fees announced for 1 April 2023
1 February 2023 - These fee increases are an important step to ensuring the MHRA has the resources it needs ...
Posted by Michael Wonder on 01 Feb 2023
Somatrogon for treating growth disturbance in people 3 years and over
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...